Drugs / ASC47
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06972992 | Apr → Sep 2025 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT06427590 | Jul → Dec 2024 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC47 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06972992 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of ASC47” NCT06427590 ↗ |